BioNTech (NASDAQ:BNTX) Given New $130.00 Price Target at HC Wainwright

BioNTech (NASDAQ:BNTX) had its price target lowered by HC Wainwright from $140.00 to $130.00 in a report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

BNTX has been the topic of several other research reports. Bank of America reiterated a “buy” rating and issued a $128.00 target price on shares of BioNTech in a report on Tuesday, March 10th. Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a research report on Friday, January 23rd. Truist Financial upgraded BioNTech to a “strong-buy” rating in a research note on Wednesday, March 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research report on Friday, January 9th. Finally, The Goldman Sachs Group restated a “buy” rating on shares of BioNTech in a research note on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BioNTech has an average rating of “Moderate Buy” and a consensus price target of $133.07.

BioNTech Price Performance

Shares of BioNTech stock opened at $88.88 on Tuesday. The company has a current ratio of 7.54, a quick ratio of 7.49 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $102.90 and a 200-day simple moving average of $101.41. The stock has a market capitalization of $22.34 billion, a price-to-earnings ratio of -16.96 and a beta of 1.51. BioNTech has a 1-year low of $79.52 and a 1-year high of $124.00.

Institutional Trading of BioNTech

A number of hedge funds have recently modified their holdings of BNTX. Dodge & Cox grew its holdings in shares of BioNTech by 315.7% during the 3rd quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock worth $359,676,000 after purchasing an additional 2,769,654 shares in the last quarter. GSK plc acquired a new position in shares of BioNTech in the fourth quarter valued at $84,711,000. BNP Paribas Financial Markets lifted its position in BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after purchasing an additional 474,796 shares during the period. Bank of America Corp DE lifted its position in BioNTech by 344.4% in the third quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock worth $56,544,000 after purchasing an additional 444,332 shares during the period. Finally, Voloridge Investment Management LLC acquired a new position in shares of BioNTech in the 4th quarter valued at $41,656,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.